Wall Street analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to report earnings of ($0.73) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($0.76). Dova Pharmaceuticals reported earnings of ($0.36) per share in the same quarter last year, which indicates a negative year over year growth rate of 102.8%. The business is expected to report its next quarterly earnings results on Thursday, February 21st.
On average, analysts expect that Dova Pharmaceuticals will report full year earnings of ($2.76) per share for the current fiscal year, with EPS estimates ranging from ($2.79) to ($2.72). For the next fiscal year, analysts forecast that the company will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.70) to ($1.13). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.12. The company had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $2.66 million.
In other Dova Pharmaceuticals news, CEO Alex Sapir bought 21,700 shares of the stock in a transaction on Tuesday, August 14th. The shares were bought at an average price of $22.83 per share, with a total value of $495,411.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 55.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in DOVA. Schwab Charles Investment Management Inc. grew its stake in Dova Pharmaceuticals by 36.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 13,500 shares of the company’s stock valued at $367,000 after acquiring an additional 3,600 shares in the last quarter. Northern Trust Corp grew its stake in Dova Pharmaceuticals by 17.5% during the 1st quarter. Northern Trust Corp now owns 64,161 shares of the company’s stock valued at $1,740,000 after acquiring an additional 9,569 shares in the last quarter. BlackRock Inc. grew its stake in Dova Pharmaceuticals by 12.5% during the 1st quarter. BlackRock Inc. now owns 648,614 shares of the company’s stock valued at $17,591,000 after acquiring an additional 71,815 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Dova Pharmaceuticals by 148.6% during the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after acquiring an additional 3,195 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Dova Pharmaceuticals during the 1st quarter valued at about $220,000. 36.64% of the stock is currently owned by institutional investors.
Shares of DOVA opened at $16.89 on Thursday. Dova Pharmaceuticals has a 1-year low of $16.63 and a 1-year high of $37.00. The company has a quick ratio of 13.14, a current ratio of 13.19 and a debt-to-equity ratio of 0.17.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Recommended Story: How mutual funds make money
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.